Literature DB >> 24773077

Frailty indexes, screening instruments and their application in Belgian primary care.

E Sieliwonczyk, S Perkisas, M Vandewoude.   

Abstract

OBJECTIVES: The complex and expensive medical care for a rising number of older patients presents a significant challenge to the health care system. Identifying cost-effective preventive interventions and systematically applying them in the elderly population could help address this challenge. Frailty assessments could prove to be valuable tools by identifying at-risk individuals to which these interventions would be offered. This review seeks to provide the reader with an overview of frailty and explain how frailty assessments could contribute to daily practice.
METHODS: PubMed was searched for articles concerning frailty assessment (July 2013). Articles discussing prominent frailty models and articles primarily focused on comparing frailty assessments in the home-dwelling population were used for this article. Domus Medica was searched for guidelines concerning the use of frailty in Belgian primary care.
RESULTS: Several notable models of frailty are summarized and discussed to provide the reader with an overview of available frailty assessments. Frailty screening modalities in primary care are discussed, as well as the current recommendations for the use of frailty assessments in Belgian primary care. The advantages of a systematic frailty assessment in primary care and other settings are highlighted.
CONCLUSION: This article recommends the assessment of frailty status as a screening tool for the evaluation of the older person in primary care. An overview of available frailty models is offered for this purpose. A consensus should be reached on which model is most appropriate. The screening for frailty promotes early intervention and timely involvement of specialists with the purpose of avoiding unfavourable outcomes, such as death or disability.

Entities:  

Keywords:  Frailty models,; Frailty,; Geriatric medicine,; Primary care,; Screening instruments

Mesh:

Year:  2014        PMID: 24773077     DOI: 10.1179/2295333714Y.0000000027

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  6 in total

1.  Current situation of frailty screening tools for older adults.

Authors:  L Ma
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

2.  Measuring daily functioning in older persons using a frailty index: a cohort study based on routine primary care data.

Authors:  Willeke M Ravensbergen; Jeanet W Blom; Andrea Wm Evers; Mattijs E Numans; Margot Wm de Waal; Jacobijn Gussekloo
Journal:  Br J Gen Pract       Date:  2020-11-26       Impact factor: 5.386

3.  Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty.

Authors:  Samuel Golpanian; Darcy L DiFede; Aisha Khan; Ivonne Hernandez Schulman; Ana Marie Landin; Bryon A Tompkins; Alan W Heldman; Roberto Miki; Bradley J Goldstein; Muzammil Mushtaq; Silvina Levis-Dusseau; John J Byrnes; Maureen Lowery; Makoto Natsumeda; Cindy Delgado; Russell Saltzman; Mayra Vidro-Casiano; Marietsy V Pujol; Moisaniel Da Fonseca; Anthony A Oliva; Geoff Green; Courtney Premer; Audrey Medina; Krystalenia Valasaki; Victoria Florea; Erica Anderson; Jill El-Khorazaty; Adam Mendizabal; Pascal J Goldschmidt-Clermont; Joshua M Hare
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2017-10-12       Impact factor: 6.053

4.  Multidimensional instruments with an integral approach to identify frailty in community-dwelling people: protocol for a systematic psychometric review.

Authors:  Juan José Zamora-Sánchez; Vicente Gea-Caballero; Iván Julián-Rochina; Lina Jódar-Fernández; Iris Lumillo-Gutiérrez; Meritxell Sastre-Rus; Ana-María Urpí-Fernández; Edurne Zabaleta-Del-Olmo
Journal:  BMJ Open       Date:  2019-12-15       Impact factor: 2.692

5.  Rationale and design of the allogeneiC human mesenchymal stem cells (hMSC) in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty.

Authors:  Samuel Golpanian; Darcy L DiFede; Marietsy V Pujol; Maureen H Lowery; Silvina Levis-Dusseau; Bradley J Goldstein; Ivonne H Schulman; Bangon Longsomboon; Ariel Wolf; Aisha Khan; Alan W Heldman; Pascal J Goldschmidt-Clermont; Joshua M Hare
Journal:  Oncotarget       Date:  2016-03-15

Review 6.  What do we know about frailty in the acute care setting? A scoping review.

Authors:  Olga Theou; Emma Squires; Kayla Mallery; Jacques S Lee; Sherri Fay; Judah Goldstein; Joshua J Armstrong; Kenneth Rockwood
Journal:  BMC Geriatr       Date:  2018-06-11       Impact factor: 3.921

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.